Chugai Pharma USA

Description/ Summary: Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antib...

20, 2015 /PRNewswire/ -- Today, Chugai Pharma USA Inc. (CPUSA), a wholly-owned ... and early clin...

Inheriting the research from the parent company – Chugai Technos Corporation in Japan, we would l...

Chugai Pharmaceutical experienced unexpected demand for the drug Actemra during the pandemic, but...

As a drug manufacturer and a pioneer in biotechnological and pharmaceutical research, Chugai is a...